Antiva to tweak dosing of HPV candidate Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 27 August, 2025

Expert Mammalian Protein CDMO Services—Scalable, High-Quality Biomanufacturing from Avid Bioservices! sponsored by AVID BIOSERVICES

news BioXcel to seek label update for psych drug after Phase 3 success Wugen collects $115M as it runs pivotal allogeneic CAR-T trial Antiva to tweak dosing of HPV drug, seek funding for new trial following mixed early data Summit partner Akeso says PD-1xVEGF drug hits OS significance in China cancer study Regeneron claims Phase 3 win for a lesser-known rare disease drug

Sep 04 11:00am ET Not just a tool: How AI agents become trial teammates sponsored by Medable Sep 09 11:30pm ET How ctDNA can assist in critical nonoperative management decisions sponsored by Haystack MRD Sep 23 11:00am ET Data you can trust: Setting the bar for ML/LLM-extracted real-world data sponsored by Flatiron Sep 25 11:00am ET Leveraging acoustic focusing for fast and precise high-parameter flow cytometry panels sponsored by Thermo Fisher Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

Endpoints News returns to Boston’s State Room to announce the 2025 class of biotechs worth watching. Join the live unveiling and see the industry’s next chapter come into focus. Which biotechs will make the leap? Join us.

endpoints pharma Sanofi hires Novartis veteran Marcia Kayath as chief medical officer Prasad's return to FDA comes with fewer titles and a seemingly lower profile White House officials link pharma tariffs with ‘most favored nation’ pricing program PhRMA loses appeals court challenge to Oregon drug price transparency law

in case you missed it 1. Lilly will seek approval of GLP-1 pill after successes in patients with both obesity and diabetes 2. Novartis pays $30M to Leqembi creator for access to blood-brain barrier tech 3. Exclusive: Neuro startup Leal raises $30M Series A for schizophrenia and ALS trials 4. News Briefing Incannex’s stock rallies on anxiety disorder data; Appia Bio closes its doors 5. BARDA awards nearly $20M to flu vaccine maker Osivax, following mRNA pullback